

HealthCare Global Enterprises Ltd. reports FY2017 results

**Annual Revenue growth of 20% and EBITDA growth of 24% (y-o-y)
PAT of INR 222 mn and EPS of INR 2.69 per share for full year**

Bengaluru, May 24, 2017: HealthCare Global Enterprises Limited (“HCG”) today announced its financial results for the fiscal year and quarter ended March 31, 2017 (“FY17” and “Q4 FY17”).

Highlights for the year ended March 31, 2017 (FY17)

- Consolidated Income from Operations (“Revenue”) was **INR 7,001 mn** as compared to **INR 5,842 mn** in the previous year, reflecting a year-on-year increase of **20%**.
- Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was **INR 1,050 mn** as compared to **INR 848 mn** in the previous year, reflecting a year-on-year increase of **24%**.
- Consolidated Profit before Taxes and Exceptional items (“PBT”) was **INR 348 million** as compared to **INR 64 mn** in the previous year, reflecting a year-on-year increase of **448%**.
- Consolidated Profit after Taxes and Minority Interest (“PAT”) was **INR 222 million** as compared to a **loss of INR 15 mn** in the previous year.
- EBITDA excluding losses from new centers was **INR 1,119 mn**, reflecting a margin of **17.6%**.

Highlights for the fourth quarter ended March 31, 2017 (Q4 FY17)

- Consolidated Income from Operations (“Revenue”) was **INR 1,824 mn** as compared to **INR 1,550 mn** in corresponding quarter of the previous year, reflecting a year-on-year increase of **18%**.
- Consolidated Profit Before Other Income, Depreciation and Amortization, Finance Costs, Exceptional Items and Taxes (“EBITDA”) was **INR 300 mn** as compared to **INR 249 mn** in the corresponding quarter of the previous year, reflecting a year-on-year increase of **20%**.
- Consolidated Profit before Taxes and Exceptional items (“PBT”) was **INR 117 million** as compared to **INR 29 mn** in the corresponding quarter of the previous year, reflecting a year-on-year increase of **305%**.
- Consolidated Profit after Taxes and Minority Interest (“PAT”) was **INR 69 million** as compared to **INR 29 mn** in the corresponding quarter of the previous year.
- EBITDA excluding losses from new centers was **INR 309 mn**, reflecting a margin of **19.3%**.

INR million except earnings per share

Period Ended March 31	Q4-FY17	Q4-FY16	Growth (y-o-y)	FY17	FY16	Growth (y-o-y)
Income from Operations	1,824	1,550	17.7%	7,001	5,842	19.8%
EBITDA⁽¹⁾	300	249	20.2%	1,050	848	23.9%
<i>EBITDA Margin (%)</i>	16.4%	16.1%		15.0%	14.5%	
PBT⁽²⁾	117	29	304.9%	348	64	447.6%
<i>PBT Margin (%)</i>	6.4%	1.9%		5.0%	1.1%	
PAT⁽³⁾	69	29	140.4%	222	(15)	-
<i>PAT Margin (%)</i>	3.8%	1.9%		3.2%	-0.2%	
Earnings Per Share	0.90	(1.83)	-	2.69	(2.43)	-

(1) Profit before other income, depreciation and amortization, finance costs, exceptional items and taxes

(2) Profit / (Loss) before tax and exceptional items

(3) Profit / (Loss) for the period after taxes and minority interests

Business Updates for Q4

- Strong growth in Gujarat further strengthening HCG's market leadership in the state
- New cancer centers at Kalaburagi, Vadodara and Visakhapatnam continued to ramp satisfactorily resulting in the significant reduction in overall losses from new centers in the quarter
- New comprehensive cancer centre in Kanpur commenced operations
- New Milann centres in Delhi, Mumbai and Chandigarh contributing strong revenue growth in the quarter

Commenting on the results, **Dr. B.S. Ajaikumar, Chairman and CEO, HealthCare Global Enterprises Ltd.** said, *"We are pleased to report strong results for Q4 and the fiscal year 2017, which incidentally marks the first full year since HCG went public. We are particularly pleased with the progress we have made over the year strengthening our presence in Gujarat and also the performance of our new cancer centers, which are nearing breakeven point ahead of plan. Apart from Gujarat, we are also very positive about our growth in Maharashtra with the upcoming launch of three new comprehensive cancer centers, which include Borivali, Nagpur and South Mumbai, and significant expansion and strengthening of relationship with our partner in Nasik. When these centers start functioning, we will have a strong leadership position in the state of Maharashtra. I would also like to announce that a new flagship comprehensive cancer center is being established in Gurgaon, NCR, which will have the most advanced technology in cancer care with a potential for proton therapy. With our recently launched center in Kanpur, upcoming center in Jaipur, we can now more effectively serve cancer patients in Northern India. I am very happy with the progress we have made over the year towards making high quality cancer care accessible to all."*

Q4 and FY17 Earnings Call

The company will conduct a one hour conference call at **6:00 PM IST on Wednesday May 24, 2017** where the management will discuss insights about the company's performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is **+91 22 3960 0644 / +91 22 3940 3977**. Other numbers are listed in the conference call invite which is uploaded on the stock exchange and posted on our website.

About HCG Enterprises Ltd.:

HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 18 comprehensive cancer centers across India, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies required for the effective diagnosis and treatment of cancer under one roof. HCG has pioneered the introduction and adoption of several technologies in the country including stereotactic radiosurgery, robotic radiosurgery and the use of genomics for personalized treatment of cancer. Under the "Milann" brand, HCG operates 7 fertility centers. **For further information**, visit www.hcgel.com or **contact: Company Secretary and Compliance Officer: Sunu Manuel, investors@hcgoncology.com**